Monte Rosa Therapeutics (GLUE) EBITDA (2020 - 2026)

Monte Rosa Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$45.4 million for Q1 2026.

• In Q1 2026, EBITDA fell 196.82% year-over-year to -$45.4 million; the TTM figure through Mar 2026 stood at -$131.4 million (down 2482.29% YoY), while the FY2025 annual figure was -$39.1 million, up 46.68% from the prior year.
• EBITDA was -$45.4 million for Q1 2026 at Monte Rosa Therapeutics, up from -$46.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $46.9 million in Q1 2025 to a low of -$46.7 million in Q4 2025.
• Historically, EBITDA has averaged -$23.7 million across 5 years, with a median of -$29.9 million in 2022.
• Biggest YoY gain for EBITDA was 246.89% in 2025; the steepest drop was 476.64% in 2025.
• A 5-year view of EBITDA shows it stood at -$29.9 million in 2022, then decreased by 15.33% to -$34.5 million in 2023, then soared by 135.93% to $12.4 million in 2024, then plunged by 476.64% to -$46.7 million in 2025, then rose by 2.77% to -$45.4 million in 2026.
• The last three EBITDA figures came in at -$45.4 million (Q1 2026), -$46.7 million (Q4 2025), and -$27.0 million (Q3 2025), per Business Quant data.